Results 341 to 350 of about 331,561 (389)
Some of the next articles are maybe not open access.
Intravenous immunoglobulin therapy in thrombocytopenic infectious mononucleosis
Clinical & Laboratory Haematology, 1989Severe haemorrhagic thrombocytopenia in infectious mononucleosis with positive Epstein-Barr virus (EBV) serology remains a threatening clinical problem. Although rare, fatalities have been reported. We present clinical, haematological and serological details of two patients with diffuse bleeding associated with this disease who failed conventional ...
A S, Duncombe +3 more
openaire +2 more sources
Review: intravenous immunoglobulin therapy and thromboembolic complications
Lupus, 2005Intravenous immunglobulin (IVIg) is used to treat a number of immune-deficiences and autoimmune diseases. Safety concerns related to a number of reported thromboembolic complications prompted us to review the literature. These complications happened mainly in individuals that had risk factors for thromboembolism, like advanced age, previous ...
U, Katz, Y, Shoenfeld
openaire +2 more sources
[Intravenous immunoglobulin therapy].
La Revue du praticien, 2005Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human IgG that are obtained from pools of healthy blood donors. They can be used at low dose in the substitutive therapy of patients with primary or secondary immune deficiencies, or at high dose as an immunomodulatory agent in a large number of autoimmune and/or systemic ...
openaire +1 more source
Intravenous Immunoglobulin Therapy and Systemic Lupus Erythematosus
Clinical Reviews in Allergy & Immunology, 2005Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with diverse manifestations. We suggest that intravenous immunoglobulin (IVIg) therapy may be beneficial and safe for various manifestations in SLE. A structured literature search of articles published on the efficacy of IVIg in the treatment of SLE between 1983 and 2005 was ...
Gisele, Zandman-Goddard +2 more
openaire +2 more sources
Intravenous and subcutaneous immunoglobulin G replacement therapy
Allergy and Asthma Proceedings, 2016Human polyclonal immunoglobulin G (IgG) for therapeutic use has been available for decades. This drug was developed for treatment of antibody deficiency (replacement therapy), although its use has expanded into many anti-inflammatory and immunomodulatory applications in recent years. This review focuses on IgG prescribing for replacement therapy.
openaire +2 more sources
Meningitis and Hepatitis Complicating Intravenous Immunoglobulin Therapy
Annals of Pharmacotherapy, 1996OBJECTIVE: To report a case of concomitant meningitis and hepatitis complicating the use of intravenous immune globulin (IVIG). CASE SUMMARY: A 39-year-old African-American woman with an autoimmune syndrome developed both acute meningitis and hepatitis following administration of IVIG. These resolved over several days and left no sequellae. DISCUSSION:
A F, Shorr, K E, Kester
openaire +2 more sources
Intravenous immunoglobulin therapy for acute cerebellar ataxia
Acta Paediatrica, 2003A case of acute cerebellar ataxia without any prodromal illness showed cerebellar hypoperfusion on 123I‐iodoamphetamine single photon emission computed tomography. The symptoms did not resolve spontaneously or with methylprednisolone pulse therapy but disappeared rapidly with intravenous immunoglobulin therapy.
openaire +2 more sources
Adverse events associated with intravenous immunoglobulin therapy
International Immunopharmacology, 2006In addition to its U.S. Food and Drug Administration (FDA) approved conditions, immune globulin intravenous (IGIV) is now being used to treat a vast array of autoimmune disorders. Some of the reasons for this overall increase in the use of IGIV include its effectiveness and safety.
openaire +2 more sources